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Short Report
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Abstract
Background
Current guidelines document persistent rectal bleeding as an alarm symptom in 
patients presenting to primary care. We studied whether a faecal immunochemical 
test (FIT) could assist in their assessment.
Methods
From December 2015, FIT were was routinely available to Primary Care when 
assessing patients with new-onset bowel symptoms: general practitioners (GP) were 
encouraged to include faecal haemoglobin concentration (f-Hb) within any referral to 
Secondary Care. Results with f-Hb ≥10 μg Hb/g faeces were defined as positive. The 
incidence of significant bowel disease (SBD: colorectal cancer [CRC], higher-risk 
adenoma [HRA: any > 1 cm, or 3 or more] and inflammatory bowel disease [IBD]) at 
subsequent colonoscopy, referred symptoms, and f-Hb were recorded.
Results
Of 1,447 patients with a FIT result and colonoscopy outcome, SBD was diagnosed in 
296 patients (20.5%; 95 with CRC, 133 with HRA, and 68 with IBD). 462 patients 
(31.9%) reported rectal bleeding: 294 had f-Hb ≥10 µg Hb/g faeces. At colonoscopy, 
105/294 had SBD versus 14/168 with rectal bleeding and f-Hb <10 µg Hb/g faeces (p 
< 0.0001), comprising one case of CRC (0.6%), 12 HRA (7.1%), and one new case 
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of IBD (0.6%); further, the single cancer and eight of the 12 HRA were located in the 
descending colon.
Conclusion
Patients with rectal bleeding and f-Hb <10 µg Hb/g faeces are unlikely to have SBD 
and could be investigated by sigmoidoscopy alone. Using FIT to guide investigation 
of patients with rectal bleeding is a rational and practical way forward.
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Introduction
Rectal bleeding can be a symptom of underlying colorectal disease and convention 
dictates that, as such, potential cancer must be considered. The National Institute for 
Health and Care Excellence (NICE) guideline NG12 states: “Refer adults using a 
suspected cancer pathway referral for colorectal cancer (CRC) if aged 50 and over 
with unexplained rectal bleeding …and consider referral for CRC in adults aged 
under 50 with rectal bleeding and unexplained …abdominal pain, change in bowel 
habit, weight loss, or iron‑deficiency anaemia”.1   The Scottish guidelines also 
recommend urgent referral for “repeated rectal bleeding without an obvious anal 
cause”.2  
Measurement of faecal haemoglobin concentration (f-Hb) with a faecal 
immunochemical test (FIT) has been advocated as a good rule-out test for 
significant bowel disease (SBD)3. NICE Diagnostics Guidance (DG30) recommends 
the use of faecal immunochemical tests for haemoglobin (FIT) at a threshold of <10 
µg Hb/g faeces, but only in “people without rectal bleeding but with unexplained 
symptoms that do not meet the criteria for a suspected cancer pathway referral”.4  
However, patients reporting rectal bleeding may not have detectable f-Hb: we 
reported that rectal bleeding symptoms associated with undetectable f-Hb carries a 
low risk of SBD.5). We determined whether using FIT with a cut-off of <10 µg Hb/g 
faeces could assist in the assessment of patients presenting to primary care with 
rectal bleeding.
Methods
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The methods used have been previously detailed.5 In summary, from December 
2015, quantitative FIT analysis was available to primary care. If patients presented 
with new-onset lower bowel symptoms, general practitioners (GP) were 
recommended to request f-Hb. Patients were instructed to collect a single sample of 
faeces and to return the FIT device immediately to the GP surgery and they were 
then delivered to Blood Sciences, Ninewells Hospital and Medical School, Dundee. 
Analysis was performed on one HM-JACKarc analyser (Hitachi Chemical 
Diagnostics Systems Co., Ltd, Tokyo, Japan). Results with f-Hb ≥10 μg Hb/g faeces 
were defined as positive. Patients referred to endoscopy were investigated within six 
weeks of referral. Any diagnosis of significant bowel disease (SBD: colorectal cancer 
[CRC], higher-risk adenoma [HRA: any > 1 cm, or 3 or more] and inflammatory 
bowel disease [IBD]) was confirmed by a consultant pathologist.  The symptoms 
reported by GPs on patient referral forms submitted to secondary care were 
collected to allow a subgroup of those reporting rectal bleeding to be defined.  
Clinical outcomes of those reporting rectal bleeding were compared between those 
with f-Hb above and those below the f-Hb cut-off of 10 µg Hb/g faeces. Chi-square 
tests were performed using MedCalc statistical software (MedCalc Software, 
Mariakerke, Belgium).
Results
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Of 1,447 patients with a f-Hb and colonoscopy outcome seen in the first year of the 
service, SBD was diagnosed in 296 patients (20.5%; 95 with CRC, 133 with HRA 
and 68 with IBD).  667 (46.1%) of the 1,447 had f-Hb <10 µg Hb/g faeces.
462 of investigated patients (31.9%) reported rectal bleeding as a symptom, of whom 
2934 had f-Hb ≥10 µg/g faeces. At colonoscopy, 105/2934 (35.7%) patients with 
rectal bleeding and f-Hb ≥10 µg/g faeces had SBD versus 14/168 (8.,3%) with rectal 
bleeding and f-Hb <10 µg Hb/g faeces (p < 0.0001) (Table 1). In the patients with 
rectal bleeding and f-Hb ≥10 µg/g faeces, there were 25 cases of CRC (8.5%), 39 
HRA (13.3%), and 25 cases of IBD (14.0%).  In contrast, of the 168 patients with 
rectal bleeding and a f-Hb <10 µg Hb/g faeces, there was one case of CRC (0.6%), 
12 HRA (7.1%), and one new case of IBD (0.6%); further, the single cancer and 
eight of the 12 HRA were found in the descending colon.
Clearly, rRectal bleeding with f-Hb <10 µg Hb/g faeces is associated with a very low 
yield of SBD. Further, in this cohort, the clear majority of the SBD could have been 
detected by sigmoidoscopy alone, missing only four HRA.  
If patients with rectal bleeding and f-Hb <10 µg Hb/g faeces had been triaged to 
sigmoidoscopy rather than full colonoscopy, this would have saved endoscopy 
resource without detriment to the patient; if a colonoscopy equates to two points of 
endoscopy time, and a sigmoidoscopy one point of endoscopy time, then 168 units 
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would have been saved over the year.  Even more could be saved by watching and 
waiting those patients with irregular symptoms.
Discussion
FIT have been recommended for the assessment of patients presenting in primary 
care with lower bowel symptoms:3,4 Moreover, f-Hb is the most important factor to be 
considered when deciding which patients would benefit most from referral.6  
Further,and a low f-Hb can be used in primary care as a rule-out test to exclude 
SBD.3-5 However, rectal bleeding, with or without other lower bowel symptoms, is 
generally considered as a “red flag” symptom,1,2 requiring urgent referral, 
irrespective of the f-Hb.  Here, we have shown that patients reported to have rectal 
bleeding are unlikely to have SBD if f-Hb <10 µg Hb/g faeces.  In contrast, more than 
one-third of such patients with f-Hb >10 µg Hb/g faeces had SBD.
Patients presenting with rectal bleeding harbour real fears and need an explanation. 
They require an objective assessment; a full history, clinical examination, and a full 
blood count are essential. We have shown that a FIT test can could provide further 
objective evidence of the risk of underlying SBD. Furthermore, we have 
demonstrated that, in the presence of a f-Hb <10 µg Hb/g faeces, patients with 
persistent rectal bleeding can be safely investigated by sigmoidoscopy alone thereby 
enabling more efficient use of endoscopy resources.  Safety-netting measures 
should also be in place for these patients if they continue to experience rectal 
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bleeding and/or other symptoms due to the small chance that SBD may not be 
detected at sigmoidoscopy. Our results indicate that using FIT to guide investigation 
of patients with rectal bleeding is a rational and practical way forward and that 
current referral guidelines require further attention.  
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Table 1. Prevalence of significant bowel disease (SBD), encompassing colorectal 
cancer (CRC), higher-risk adenoma (HRA) and inflammatory bowel disease (IBD) in 
patients with rectal bleeding stratified by faecal haemoglobin concentration (f-Hb). 
All patients
f-Hb <10 µg 
Hb/g faeces 
and rectal 
bleeding 
f-Hb ≥10 µg 
Hb/g faeces and 
rectal bleeding 
p-value*
n % n % n %
No of 
colonoscopies 1447 168 293
No with CRC 95 6.6 1 0.6 25 8.5 <0.001
No with HRA 133 9.2% 12 7.1 39 13.3 0.424
No with IBD 68 4.7% 1 0.6 410 13.714.0 <0.0001
Total SBD (CRC + 
HRA +IBD) 296 20.5 14 8.3 105 35.8 <0.0001
* p-value is for comparison of those with f-Hb <10 µg Hb/g faeces and ≥10 µg Hb/g faeces 
who had rectal bleeding.
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